|

TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors

RECRUITINGPhase 1Sponsored by Treeline Biosciences, Inc.
Actively Recruiting
PhasePhase 1
SponsorTreeline Biosciences, Inc.
Started2026-08-05
Est. completion2030-08-29
Eligibility
Age18 Years+
Healthy vol.Accepted

Summary

The purpose of this first-in-human study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of TLN-499 in combination with venetoclax in participants with relapsed/refractory solid tumors.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

1. Adults ≥18 years of age
2. Histologically confirmed relapsed/refractory SCLC, neuroendocrine cancer, malignant pleural mesothelioma, or synovial sarcoma
3. Measurable disease per RECIST v1.1 or mRECIST
4. ECOG performance status 0-1
5. Adequate hematologic, hepatic, renal, and coagulation function.
6. Life expectancy ≥12 weeks
7. Signed informed consent

Exclusion Criteria:

1. Active brain metastases
2. Major surgery or severe trauma within 4 weeks before first dose
3. Significant uncontrolled medical conditions preventing study participation
4. Use of prohibited concomitant medications
5. Previous conditions that would interfere with study assessments or safety

Conditions6

CancerLung CancerMalignant Pleural Mesotheliomas (Mpm)Neuroendocrine CancerSmall Cell Lung Cancer (SCLC)Synovial Sarcomas

Interventions2

Related trials

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.